Market Overview:
The global benign prostatic hyperplasia therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of benign prostatic hyperplasia, rising geriatric population, and technological advancements in the field of benign prostatic hyperplasia therapeutics. However, the high cost of treatment and lack of awareness about benign prostatic hyperplasia are some factors that may restrain the growth of this market during the forecast period. Based on type, the global benign prostatic hyperplasia therapeutics market is segmented into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor (PDE-5 inhibitors), and others.
Product Definition:
Benign Prostatic Hyperplasia Therapeutics is a medical term used to describe the use of medications and other treatments to improve symptoms associated with benign prostatic hyperplasia (BPH), a common condition in older men. Benign prostatic hyperplasia occurs when the prostate gland becomes enlarged, which can cause difficulty urinating, straining while urinating, and a feeling of not having fully emptied the bladder after going to the bathroom. While there is no cure for BPH, medications and other treatments can often help relieve symptoms.
Alpha Blocker:
Alpha blockers are used to treat prostate cancer and benign prostatic hyperplasia. They work by decreasing the activity of the hormone known as “dihydrotestosterone”, which is responsible for growth of prostate cancer cells and BPH cells (benign prostatic hyperplasia). The drug works by blocking an enzyme that is responsible for converting testosterone into dihydrotestosterone.
5-Alpha Reductase Inhibitor:
5-ALPHA REDUCTASE INHIBITOR is an oral drug that decreases the amount of prostate-specific antigen (PSA) produced by the body. It works by decreasing the activity of a certain enzyme, which causes overproduction of testosterone in men.
The global 5-Alpha Reductase Inhibitor and it's usage in Benign Prostatic Hyperplasia market size was valued at USD 1,236.1 million in 2016.
Application Insights:
Based on application, the market is segmented into mono drug therapy, combination drug therapy and others. The other applications include surgery androgenetic alopecia prostate cancer treatment. Mono drug therapies dominated the overall application segment in terms of revenue in 2017 owing to its high therapeutic index along with few adverse effects.
Alpha blocker classification includes doxazosin, terodilators include tamsulosin and finasteride while 5-alpha reductase inhibitor includes finasteride and dutasteride are some of the drugs under this class. Combination therapies are expected to witness lucrative CAGR during forecast period due to rising awareness about BPH as well as a growing preference for combination therapies over monotherapy among patients suffering from benign prostatic hyperplasia (BPH).
Regional Analysis:
North America dominated the global BPH drug market in 2016 with a share of over 40.0%. This is due to the presence of well-established healthcare infrastructure, high patient awareness levels coupled with relatively higher healthcare expenditure levels in this region as compared to other regions. Moreover, increasing prevalence of Benign Prostatic Hyperplasia (BPH) and related bladder disorders such as urge urinary incontinence and bladder obstruction that result from an unhealthy lifestyle is also one major factor responsible for the large share held by North America.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to rising disposable income leading to increased demand for various health products & services resulting in improved quality of life coupled with growing medical tourism industry supported by low cost treatment options available in this region thereby boosting growth prospects for APAC regional market during forecast period. Furthermore, government initiatives encouraging people suffering from BPH & related symptoms are also expected favorably impact growth over coming years (Ref).
Growth Factors:
- Increasing prevalence of benign prostatic hyperplasia (BPH) due to aging population
- Growing demand for minimally invasive and non-invasive treatments for BPH
- Rising awareness about the available treatment options for BPH
- Technological advancements in benign prostatic hyperplasia therapeutics market
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Benign Prostatic Hyperplasia Therapeutics Market Research Report
By Type
Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others
By Application
Mono Drug Therapy, Combination Drug Therapy
By Companies
Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH and Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Merck and Co., Pfizer, Sanofi, Teva Pharmaceutical Industries Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Benign Prostatic Hyperplasia Therapeutics Market Report Segments:
The global Benign Prostatic Hyperplasia Therapeutics market is segmented on the basis of:
Types
Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Mono Drug Therapy, Combination Drug Therapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Allergan plc
- Astellas Pharma
- Boehringer Ingelheim Pharma GmbH and Co. KG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck and Co.
- Pfizer
- Sanofi
- Teva Pharmaceutical Industries Limited
Highlights of The Benign Prostatic Hyperplasia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alpha Blocker
- 5-Alpha Reductase Inhibitor
- Phosphodiesterase-5 Inhibitor
- Others
- By Application:
- Mono Drug Therapy
- Combination Drug Therapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Benign Prostatic Hyperplasia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Benign Prostatic Hyperplasia Therapeutics is a drug developed by Benign Prostatic Hyperplasia Therapeutics, Inc. that is used to treat benign prostatic hyperplasia (BPH).
Some of the key players operating in the benign prostatic hyperplasia therapeutics market are Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH and Co. KG, Eli Lilly and Company, GlaxoSmithKline plc, Merck and Co., Pfizer, Sanofi, Teva Pharmaceutical Industries Limited.
The benign prostatic hyperplasia therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Benign Prostatic Hyperplasia Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Benign Prostatic Hyperplasia Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Benign Prostatic Hyperplasia Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Benign Prostatic Hyperplasia Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Benign Prostatic Hyperplasia Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Benign Prostatic Hyperplasia Therapeutics Market Size and Y-o-Y Growth
4.5.2 Benign Prostatic Hyperplasia Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Alpha Blocker
5.2.2 5-Alpha Reductase Inhibitor
5.2.3 Phosphodiesterase-5 Inhibitor
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Mono Drug Therapy
6.2.2 Combination Drug Therapy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Benign Prostatic Hyperplasia Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Alpha Blocker
9.6.2 5-Alpha Reductase Inhibitor
9.6.3 Phosphodiesterase-5 Inhibitor
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Mono Drug Therapy
9.10.2 Combination Drug Therapy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Alpha Blocker
10.6.2 5-Alpha Reductase Inhibitor
10.6.3 Phosphodiesterase-5 Inhibitor
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Mono Drug Therapy
10.10.2 Combination Drug Therapy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Alpha Blocker
11.6.2 5-Alpha Reductase Inhibitor
11.6.3 Phosphodiesterase-5 Inhibitor
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Mono Drug Therapy
11.10.2 Combination Drug Therapy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Alpha Blocker
12.6.2 5-Alpha Reductase Inhibitor
12.6.3 Phosphodiesterase-5 Inhibitor
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Mono Drug Therapy
12.10.2 Combination Drug Therapy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Alpha Blocker
13.6.2 5-Alpha Reductase Inhibitor
13.6.3 Phosphodiesterase-5 Inhibitor
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Mono Drug Therapy
13.10.2 Combination Drug Therapy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Benign Prostatic Hyperplasia Therapeutics Market: Competitive Dashboard
14.2 Global Benign Prostatic Hyperplasia Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Allergan plc
14.3.3 Astellas Pharma
14.3.4 Boehringer Ingelheim Pharma GmbH and Co. KG
14.3.5 Eli Lilly and Company
14.3.6 GlaxoSmithKline plc
14.3.7 Merck and Co.
14.3.8 Pfizer
14.3.9 Sanofi
14.3.10 Teva Pharmaceutical Industries Limited
